SIRO Clinpharm appoints chief executive

Takes responsibility for expanding business across the US, Europe and Asia

SIRO Clinpharm, a clinical research organisation headquartered in Mumbai, India has appointed Gopakumar Menon as chief executive to build and enhance the firm’s biopharma service offering, across the US, Europe and Asia.

Menon has been working in the pharmaceutical industry for the more than 12 years in various capacities, from discovery to sales and marketing.

Prior to joining SIRO Clinpharm he worked for Boston, US-based Sciformix. He has had significant experience working with Fortune 500 companies such as Cognizant and Satyam, as well as with venture funded start-up organisations.

SIRO Clinpharm has offices in India, Malaysia, US, Israel Germany, Romania, Estonia, Greece, Czech Republic and Spain.

You may also like

Regulatory

SIRO Clinpharm expands its presence in Asia

Launches operations in Malaysia
Regulatory

SIRO Clinpharm seeks Asia Pacific growth with DreamCIS pact

Mumbai-based contract research organisation SIRO Clinpharm has formed an alliance with DreamCIS, a CRO based in Seoul, South Korea in order to build its business in the Asia Pacific region.
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Research & Development

Hamilton Health Sciences chosen for BirchBioMed burn scar treatment trial

BirchBioMed announces Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario as the first contracted clinical trial site for its Phase II/III randomised study of the naturally based compound: FS2.
Subscribe now